Obstetrics & Gynecology Science

Search

Close

Original Article
Korean J Obstet Gynecol. 2004;47(7):1285-1289. Published online July 1, 2004.
A Comparative Study of Oral and Vaginal Misoprostol Administration in Mid-trimester Pregnancy Termination.
Sung Ug Kim, Dong Hue Cho, Eun Jun Ahn, Hwan Ju Yang, Jung Heon Lee, Sung Nam Cho
Department of Obstetrics and Gynecology, College of Medicine, Chonbuk National University, Jeonju, Korea.
Abstract
OBJECTIVE
To compare the effectiveness of oral misoprostol with vaginal misoprostol administration in mid-trimester pregnancy termination after pretreatment with serial laminarias tenting. METHODS: This study was made in 50 patients for mid-trimester pregnancy termination at Department of Obstetrics and Gynecology, Chonbuk National University Hospital from January 1999 through December 2002. Twenty five women received misoprostol orally in a dose of 200 micro gram every hour for 3 doses followed by 400 micro gram every 4 hours after serial laminarias tenting. Twenty five women received misoprostol vaginally in a dose of 400 micro gram every 4 hours after serial laminarias tenting. Side effects of drug, induction to delivery interval, delivery numbers within 24 hours, curettage numbers for retained placenta, and the length of hospital stay were compared. RESULTS: The mean time of induction to delivery interval was significantly shorter in the vaginal group (15.5 +/- 12.7 vs 24.2 +/- 14.3 hours, p<0.01). The length of hospital stay was also shorter in the vaginal group (38.9 +/- 13.1 vs 47.2 +/- 14.5 hours, p<0.01). The number of patients delivered within 24 hours was more in the vaginal group (92 vs 72%, p<0.05). The side effects of misoprostol were slightly more common in the oral group than the vaginal group without statistical significance. CONCLUSION: We suspect that after serial tenting of laminarias, intravaginal misoprostol appears to be more safe and effective than oral misoprostol for mid-trimester termination.

Keywords :Mid-trimester termination;Misoprostol;Oral and vaginal administration

Go to Top